Results 71 to 80 of about 839,337 (241)

Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study

British medical journal, 2021
Objective To estimate the effectiveness of mRNA covid-19 vaccines against symptomatic infection and severe outcomes (hospital admission or death). Design Test negative design study.
Hannah Chung, Siyi He, S. Nasreen, M. Sundaram, S. Buchan, Sarah E. Wilson, Branson Chen, A. Calzavara, D. Fell, P. Austin, K. Wilson, K. L. Schwartz, K. Brown, J. Gubbay, N. Basta, S. Mahmud, C. Righolt, L. Svenson, S. MacDonald, N. Janjua, M. Tadrous, J. Kwong   +21 more
semanticscholar   +1 more source

Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database [PDF]

, 2023
Introduction: Since the first COVID-19 messenger RNA vaccines became available globally for emergency or conditional use, post-marketing surveillance activities have been implemented for the monitoring of any adverse events that might arise in daily ...
Bonaldo G., Broccoli M., Montanaro N., Motola D., Santi Laurini G.   +4 more
core   +1 more source

Multifocal lymphadenopathies with polyclonal reactions primed after EBV infection in a mRNA-1273 vaccine recipient. [PDF]

, 2022
We report a case of recurrent tender, multifocal lymphadenopathies associated with B-symptoms, clinically mimicking lymphoma in a mRNA-1273 vaccine recipient after a recent Epstein-Barr virus (EBV) infection.
Girardin, F.R., Greub, G., Livio, F., Pantaleo, G., Tzankov, A.   +4 more
core   +1 more source

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study

British medical journal, 2021
Objectives To evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2 variants and assess its effectiveness against the delta variant by time since vaccination. Design Test negative case-control study.
K. Bruxvoort, L. Sy, L. Qian, B. Ackerson, Yi Luo, Gina S. Lee, Yun Tian, A. Florea, Michael Aragones, J. Tubert, H. Takhar, J. Ku, Y. Paila, C. Talarico, H. Tseng   +14 more
semanticscholar   +1 more source

The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5

Vaccines, 2023
The aim of this study is to investigate the reactogenicity and immunogenicity of the fourth dose using monovalent mRNA vaccines after different three-dose regimens and to compare the 30 µg BNT162b2 and 50 µg mRNA-1273 vaccines.
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, Suvichada Assawakosri, Ritthideach Yorsaeng, Pornjarim Nilyanimit, Ratchadawan Aeemjinda, Nongkanok Khanarat, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Thanunrat Thongmee, Donchida Srimuan, Thaksaporn Thatsanathorn, Natthinee Sudhinaraset, Nasamon Wanlapakorn, Sittisak Honsawek, Yong Poovorawan   +16 more
doaj   +1 more source

COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge [PDF]

, 2021
Vaccine-associated enhanced respiratory disease (VAERD) was previously observed in some preclinical models of SARS and MERS coronavirus vaccines. We used the SARS-CoV-2 MA10 mouse model of acute lung injury to evaluate the immune response and potential ...
Abiona, O.M., Alvarado, G.S., Baric, R.S., Bock, K.W., Boyoglu-Barnum, S., Carfi, A., Chang, L.A., Corbett, K.S., Dinnon, K.H., III, DiPiazza, A.T., Edwards, D.K., Graham, B.S., Leist, S.R., Loomis, R.J., Mascola, J.R., Minai, M., Moliva, J.I., Moore, I.N., Morabito, K.M., Nagata, B.M., Phung, E., Ruckwardt, T.J., Schäfer, A., Sullivan, N.J., Werner, A.   +24 more
core   +2 more sources

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines

Human Vaccines & Immunotherapeutics, 2023
Certain aspects of the immunogenicity and effectiveness of the messenger ribonucleic acid (mRNA) vaccines (mRNA-1273 and BNT162b2) developed in response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are still ...
Thomas E. Hickey, Troy J. Kemp, Jimmie Bullock, Aaron Bouk, Jordan Metz, Abigail Neish, James Cherry, Douglas R. Lowy, Ligia A. Pinto   +8 more
doaj   +1 more source

NO SAFETY CONCERNS OBSERVED WHEN THE ADJUVANTED RECOMBINANT ZOSTER VACCINE (RZV) AND THE COVID-19 MRNA-1273 BOOSTER WERE CO-ADMINISTERED IN ≥50-YEAR-OLDS

International Journal of Infectious Diseases, 2023
Intro: The US CDC recommends that COVID-19 vaccines may be coadministered with other age-appropriate vaccines. There is limited data assessing outcomes, including reactogenicity, on such co-administration.
A. Naficy, P. Pirrotta, A. Kuxhausen, J. Miller, B. Leav, A. Mwakingwe-Omari   +5 more
doaj   +1 more source

Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2: Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) [PDF]

, 2023
Extension of the COVERALL (COrona VaccinE tRiAL pLatform) randomized trial showed noninferiority in antibody response of the third dose of Moderna mRNA-1273 vaccine (95.3% [95% confidence interval {CI}, 91.9%-98.7%]) compared to Pfizer-BioNTech BNT162b2 ...
Abela, Irene A, Amico, Patrizia, Amstutz, Alain, Audigé, Annette, Braun, Dominique L, Briel, Matthias, Bucher, Heiner C, Chammartin, Frédérique, Eichenberger, Anna L, Epp, Selina, Griessbach, Alexandra, Günthard, Huldrych F, Hasse, Barbara, Koller, Michael T, Kusejko, Katharina, Mueller, Nicolas J, Müller, Thomas F, Rauch, Andri, Schuurmans, Macé Matthew, Schönenberger, Christof M, Speich, Benjamin, Stoeckle, Marcel P, Swiss HIV Cohort Study and the Swiss Transplant Cohort Study, Taji Heravi, Ala, Tamm, Michael, Trkola, Alexandra   +25 more
core   +7 more sources

Racing against COVID-19: a vaccines strategy for Europe. Bruegel Policy Contribution Issue n˚7 | April 2020 [PDF]

, 2020
The fast development of vaccines is an essential part of the long-term solution to COVID-19, but vaccine development has high costs and carries the risk of high failure rates.
Veugelers, Reinhilde, Zachmann, Georg.
core   +1 more source